Research led by Wolfsonian shows anti-malaria drug could make tumours easier to treat

“This is an exciting result. We have now started a clinical trial in Oxford to see if we can show the same results in cancer patients. We hope that this existing low-cost drug will mean that resistant tumours can be re-sensitised to radiotherapy.” - Professor Gillies McKenna, lead author

The study, carried out at the Cancer Research UK Radiation Research Centre in Oxford, looked at the effect of the drug, called atovaquone, on tumours with low oxygen levels in mice, to see if it could be repurposed to treat cancer.

Source: Cancer Research UK